Ayahuasca for Depressive Disorders

37 papers and 0 clinical trials exploring ayahuasca as a treatment for depressive disorders.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
IndicationApproximately 260 million people worldwide are affected by depression.

Depressive Disorders

Depressive disorders, particularly major depressive disorder (MDD), are significant contributors to global mental health issues. Research into the therapeutic potential of psychedelics, such as psilocybin and ketamine, offers promising avenues for treatment, especially for cases that are resistant to conventional therapies.

Full Depressive Disorders profile

Academic Research

37 papers
Open Accessindividual

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

In a crossover RCT of 31 healthy male volunteers, an ayahuasca‑inspired formulation combining intranasal N,N‑DMT (up to 100 mg) with an orodispersible 100 mg harmine tablet produced robust, phenomenologically rich psychedelic experiences characterised by psychological insights and emotional breakthroughs, low challenging effects, and mainly positive persisting effects at 1 and 4 months. The compound showed good psychological safety and tolerability with no increases in psychopathology or changes in trait measures, indicating potential to support psychotherapeutic applications.

Published
Journal
Frontiers in Psychiatry
Authors
Aicher, H. D., Dornbierer, D. A., Mueller, M. J., Scheidegger, M.
Open Accessindividual

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

This Phase 2a open‑label, dose‑escalation study in six patients with treatment‑resistant depression found that a single‑day session of vapourised N,N‑dimethyltryptamine produced rapid and sustained reductions in depressive symptoms (mean MADRS change −22 at Day 7 and −17 at one month), with 83.3% response and 66.7% remission at Day 7 and 66.7% response and 50% remission at one month. The authors highlight the non‑invasive, short‑acting delivery as a practical advantage that could improve accessibility of psychedelic-assisted interventional psychiatry.

Published
Journal
MedRvix
Authors
Almeida, R., Araújo, D. B., Arcoverde, E., Arichelle, F., Barbosa, D. C., Barros, H., Bolcont, R., Falchi-Carvalho, M., Florence-Vilela, R., Galvão-Coelho, N. L., Laborde, S., Macedo, R. K. A., Montanini, D., Palhano-Fontes, F., Pantrigo, E. J., Silva, S. R. B., Teixeira, E., Wießner, I.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Depressive Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Depressive Disorders trials Full Ayahuasca profile Full Depressive Disorders profile